The Clinical utility of Interleukin-17A rs2275913 polymorphism with colorectal cancer in Egyptian patients.

The worldwide incidence of colorectal cancer (CRC) is roughly two million new instances each year throughout the world, according to the World Health Organization 2022. CRC is the third most prevalent disease and the second most common cancer in terms of fatality. People diagnosed with colorectal cancer in the early stages have a five-year survival rate of roughly 95%, but people identified with the disease in the later stages have a survival rate of approximately 12%. There are a number of variables that contribute to the development of CRC, these factors include both hereditary and environmental influences. We aimed to investigate the clinical utility of Interleukin (IL)-17A rs2275913 polymorphism to assess its association with CRC in Egyptian patients and the ability of using it as a non-invasive biomarker to assist in diagnosis of colorectal cancer. This case-control study included 75 subjects. Of these, 35 were CRC cases, 20 inflammatory bowel disease (IBD) patients and 20 normal control persons. Blood was collected and DNA extracted. The rs2275913 of IL-17A was genotyped using the Real-Time polymerase chain reaction (PCR). In CRC patient's group, (5.71%) had the homozygous AA genotype, (40%) the heterozygous GA genotype and (54.29%) the wild GG genotype. While in IBD group (15%) had the homozygous AA genotype, (40%) the heterozygous GA genotype and (45%) the wild GG genotype. In the normal control group, no one had the homozygous AA genotype, but (45%) had the heterozygous GA genotype and (55%) the wild type of GG genotype. However, there was no statistically significant substantial variation amongst the three groups (p>0.05). In conclusion, our study demonstrated no association of IL-17A rs2275913 with both CRC and IBD in the Egyptian population.